Haleon plc, known by its ticker symbol HLN, is a prominent player in the healthcare and consumer wellness industry. The company's roots trace back to 2022 when it was demerged from GlaxoSmithKline plc, marking its independent journey in the global consumer healthcare market. Haleon's business activities revolve around the development, manufacturing, and marketing of a wide range of consumer healthcare products. These products span across three primary categories: oral care, pain relief, and digestive health. The company's operations sprawl across...
No data available.
No data available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | ZTS | Zoetis Inc. | 56.15 Bn | 21.18 | 5.98 | 7.27 Bn |
| 2 | TAK | Takeda Pharmaceutical Co Ltd | 48.92 Bn | 221.13 | 1.66 | 36.24 Bn |
| 3 | HLN | Haleon plc | 46.13 Bn | 25.59 | 3.29 | - |
| 4 | TEVA | Teva Pharmaceutical Industries Ltd | 35.27 Bn | 49.54 | 2.10 | 17.07 Bn |
| 5 | UTHR | UNITED THERAPEUTICS Corp | 21.76 Bn | 17.11 | 6.95 | 0.00 Bn |
| 6 | VTRS | Viatris Inc | 14.87 Bn | -4.03 | 1.05 | 14.44 Bn |
| 7 | NBIX | Neurocrine Biosciences Inc | 14.08 Bn | 32.91 | 5.25 | 0.43 Bn |
| 8 | ELAN | Elanco Animal Health Inc | 11.64 Bn | 323.29 | 2.54 | 4.32 Bn |
| Current Valuation | Value | Ind Avg | Percentile |
|---|---|---|---|
| EV to Assets EV to Assets | 1.64 | 24.98 | |
| EV to Cash from Ops. EV/CFO | 24.47 | -85.40 | |
| EV to Debt EV to Debt | 5.46 | 265.88 | |
| EV to EBIT EV/EBIT | 25.84 | -32.65 | |
| EV to EBITDA EV/EBITDA | 23.16 | -29.50 | |
| EV to Free Cash Flow [EV/FCF] EV/FCF | 27.45 | -32.62 | |
| EV to Market Cap EV to Market Cap | 1.53 | -10.98 | |
| EV to Revenue EV/Rev | 5.01 | -700.14 | |
| Price to Book Value [P/B] P/B | 2.28 | 27.22 | |
| Price to Earnings [P/E] P/E | 25.59 | -122.96 |
| Dividend Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio Dividend Coverage Ratio | 3.16 | 0.34 | |
| Dividend Payout Ratio % Dividend Payout Ratio % | 40.50 | 4.81 | |
| Dividend per Basic Share Div per Share (Qtr) | 0.16 | 0.07 | |
| FCF Dividend Payout Ratio % FCF Dividend Payout Ratio % | 35.63 | 4.08 | |
| Interest Coverage Interest Coverage | 7.22 | -38.10 |
| Growth Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Capex Growth (1y) % Capex Growth (1y) % | -5.50 | -157.22 | |
| Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) | 112.82 | 44,776.25 | |
| Dividend Growth (1y) % Dividend Growth (1y) % | 247.83 | 2.81 | |
| EBIAT Growth (1y) % EBIAT Growth (1y) % | 27.60 | 24.45 | |
| EBITDA Growth (1y) % EBITDA Growth (1y) % | 9.27 | 18.14 | |
| EBIT Growth (1y) % EBIT Growth (1y) % | 11.26 | 37.66 | |
| EBT Growth (1y) % EBT Growth (1y) % | 18.36 | 108.18 | |
| EPS Growth (1y) % EPS Growth (1y) % | 36.86 | 52.88 | |
| FCF Growth (1y) % FCF Growth (1y) % | 8.54 | -54.47 | |
| Gross Profit Growth (1y) % Gross Profit Growth (1y) % | -0.12 | 25.28 |
| Liquidity Ratios | Value | Ind Avg | Percentile |
|---|---|---|---|
| Asset Utilization Ratio Asset Utilization Ratio | 0.41 | 0.50 | |
| Cash Payout Ratio Cash Payout Ratio | 0.22 | 0.02 | |
| Cash Ratio Cash Ratio (Qtr) | 0.39 | 2.10 | |
| Current Ratio Curr Ratio (Qtr) | 0.98 | 3.92 | |
| Debt to Equity Ratio Debt/Equity (Qtr) | 0.64 | -1.11 | |
| Interest Cover Ratio Interest Cover Ratio | 7.22 | -38.10 | |
| Times Interest Earned Times Interest Earned | 7.22 | -38.10 |
| Profitability | Value | Ind Avg | Percentile |
|---|---|---|---|
| EBITDA Margin % EBITDA Margin % | 21.40 | -62,432.09 | |
| EBIT Margin % EBIT Margin % | 15.52 | -63,260.88 | |
| EBT Margin % EBT Margin % | 16.71 | -66,726.96 | |
| Gross Margin % Gross Margin % | 60.70 | 8,332.72 | |
| Net Profit Margin % Net Profit Margin % | 12.80 | -66,728.37 |